1. Home
  2. TVRD vs TSAT Comparison

TVRD vs TSAT Comparison

Compare TVRD & TSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • TSAT
  • Stock Information
  • Founded
  • TVRD 2017
  • TSAT 1969
  • Country
  • TVRD United States
  • TSAT Canada
  • Employees
  • TVRD N/A
  • TSAT N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • TSAT Metal Fabrications
  • Sector
  • TVRD Health Care
  • TSAT Industrials
  • Exchange
  • TVRD Nasdaq
  • TSAT Nasdaq
  • Market Cap
  • TVRD 246.5M
  • TSAT 233.1M
  • IPO Year
  • TVRD N/A
  • TSAT 1996
  • Fundamental
  • Price
  • TVRD $26.91
  • TSAT $23.41
  • Analyst Decision
  • TVRD Strong Buy
  • TSAT
  • Analyst Count
  • TVRD 4
  • TSAT 0
  • Target Price
  • TVRD $58.50
  • TSAT N/A
  • AVG Volume (30 Days)
  • TVRD 92.7K
  • TSAT 165.1K
  • Earning Date
  • TVRD 08-21-2025
  • TSAT 08-13-2025
  • Dividend Yield
  • TVRD N/A
  • TSAT N/A
  • EPS Growth
  • TVRD N/A
  • TSAT N/A
  • EPS
  • TVRD N/A
  • TSAT N/A
  • Revenue
  • TVRD N/A
  • TSAT $372,642,710.00
  • Revenue This Year
  • TVRD N/A
  • TSAT N/A
  • Revenue Next Year
  • TVRD N/A
  • TSAT N/A
  • P/E Ratio
  • TVRD N/A
  • TSAT N/A
  • Revenue Growth
  • TVRD N/A
  • TSAT N/A
  • 52 Week Low
  • TVRD $8.13
  • TSAT $7.21
  • 52 Week High
  • TVRD $34.31
  • TSAT $27.45
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • TSAT 65.95
  • Support Level
  • TVRD N/A
  • TSAT $25.26
  • Resistance Level
  • TVRD N/A
  • TSAT $27.45
  • Average True Range (ATR)
  • TVRD 0.00
  • TSAT 1.70
  • MACD
  • TVRD 0.00
  • TSAT 0.01
  • Stochastic Oscillator
  • TVRD 0.00
  • TSAT 66.48

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About TSAT Telesat Corporation and Class B Variable Voting Shares

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

Share on Social Networks: